Professor Martin Landray
Research groups
- Accurately estimating the burden of vascular disease using electronic health records
- Analysing big data from electronic health records to understand the determinants of cardiovascular disease
- Deep phenotyping of vascular events in large-scale epidemiological studies using electronic health records
- Big Data Institute (BDI)
Websites
-
Randomised Evaluation of COVID-19 Therapy (RECOVERY)
Co-chief Investigator
-
Randomized EValuation of Effects of Anacetrapib on Lipid-modification (HPS3 / TIMI55 - REVEAL)
Chief Investigator
-
Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)
Co-principal Investigator
-
Campath, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial (3C)
Co-principal Investigator
-
Study of Heart and Renal Protection (SHARP)
Co-principal Investigator
-
UK Biobank
Lead, Health Informatics Hub; Member of Outcomes Adjudication Working Group
-
FDA Clinical Trial Transformation Initiative
Member of Steering Committee; Co-lead of Monitoring, Quality by Design, and Mobile Clinical Trials Projects
-
MRC Hubs for Trials Methodology Research
Co-principal Investigator, Oxford CTSU Hub
-
Oxford Academic Health Science Centre
Chair, Big Data and Clinical Informatics Committee
-
Oxford Academic Health Science Centre
Big Data Theme Lead
Colleges
Martin Landray
MB ChB, PhD, FRCP, FHEA, FASN, FBPhS, FESC
Professor of Medicine and Epidemiology
- Research Director, Health Data Research UK
- Acting Director, Big Data Institute
- Lead, Big Data & Computing Innovation, MRC Population Health Research Unit
- Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre
- Lead, Health Informatics Hub, UK Biobank
- Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust
Prof Landray’s work seeks to further understanding of the determinants of common diseases through the design, conduct and analysis of efficient, large-scale clinical trials and prospective cohort studies (including UK Biobank). He has led a series of major clinical trials assessing treatments for cardiovascular and kidney disease. These have enrolled over 65,000 individuals, producing results that have changed regulatory drug approvals, influenced clinical guidelines and changed prescribing practice to the benefit of patients.
He is heavily involved in efforts to streamline clinical trials, working with regulatory agencies to facilitate efficient and cost-effective trials. He is a member of the Steering Committee of the FDA Clinical Trial Transformation Initiative, leading the Monitoring, Quality by Design, and Mobile Clinical Trials projects. He is a member of the NHS Digital Research Advisory Group and the NICE Data & Analytics External Reference Group, and leads the 21st Century Clinical Trials programme for Health Data Research UK.
Prof Landray completed medical training at University of Birmingham (UK) and specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine at University of Birmingham. He continues to practise clinical medicine as an Honorary Consultant Physician in the Cardiology, Cardiac and Thoracic Surgery Directorate at Oxford University Hospitals NHS Trust. He is a Fellow of the Royal College of Physicians of London, the Higher Education Academy, the British Pharmacological Society, and the European Society of Cardiology.
Recent publications
-
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Journal article
RECOVERY Collaborative Group None. et al, (2020), N Engl J Med
-
Lopinavir-ritonavir in Hospitalised Patients with COVID-19 – a randomised, controlled, open-label, platform trial
Journal article
LINSELL L. et al, (2020), The Lancet
-
CONVENTIONAL AND GENETIC EVIDENCE ON THE ASSOCIATION BETWEEN ADIPOSITY AND CHRONIC KIDNEY DISEASE
Journal article
HERRINGTON W. et al, (2020), Journal of the American Society of Nephrology
-
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
Journal article
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group None. et al, (2020), JAMA
-
Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
Journal article
Herrington WG. et al, (2020), Clin Kidney J, 13
IN the News
BBC: The challenge of saving lives with 'big data'
The Guardian: Can smartphone drug trials improve medical care?
The Economist: Testing, Testing
Oxford Mail: City is at the forefront of disease prevention
European Heart Journal: Clinical trials: how to get closer to the right answer with less effort
Lectures, webcasts and interviews
Big Trials, Big Data, Big Potential: population health research in the 21st century
Inaugural Lecture, University of Oxford, November 2015
New Technologies for Healthcare Research
Oxford Martin School, University of Oxford, January 2016
Big Data for Efficient Clinical Trials
National Academy of Medicine, Washington DC, October 2015
Big Data in Biomedicine
Interview, Stanford Medicine, May 2015
Quality by Design for Clinical Trials
Clinical Trial Transformation Initiative, Bethesda, April 2015
Big Data in Biomedicine
Interview, Stanford Medicine, May 2014
Big Data and Drug Discovery
University of Oxford Alumni, October 2013